Literature DB >> 6420042

Prolactin response to thyrotropin-releasing hormone stimulation and dopaminergic inhibition in benign breast disease.

S Kumar, R E Mansel, L E Hughes, J S Woodhead, C A Edwards, M F Scanlon, R G Newcombe.   

Abstract

Pituitary function was tested in predefined clinical groups of benign breast disease under strictly controlled clinical and laboratory conditions. Two different tests of prolactin storage and control mechanisms, direct stimulation by thyrotropin-releasing hormone (TRH) and inhibition of dopaminergic control by domperidone, indicate a significant abnormality in patients with severe cyclical mastalgia and nodular breast disease (P less than 0.05 and P less than 0.002), but not in those with noncyclical mastalgia. No abnormalities of thyroid function were found.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6420042     DOI: 10.1002/1097-0142(19840315)53:6<1311::aid-cncr2820530615>3.0.co;2-r

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  9 in total

Review 1.  The endocrine basis of benign breast disorders.

Authors:  L Dogliotti; F Orlandi; A Angeli
Journal:  World J Surg       Date:  1989 Nov-Dec       Impact factor: 3.352

Review 2.  Epidemiology and endocrinology of benign breast disease.

Authors:  D Y Wang; I S Fentiman
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

Review 3.  Benign breast diseases.

Authors:  Carine Courtillot; Geneviève Plu-Bureau; Nadine Binart; Corinne Balleyguier; Brigitte Sigal-Zafrani; Vincent Goffin; Frédérique Kuttenn; Paul A Kelly; Philippe Touraine
Journal:  J Mammary Gland Biol Neoplasia       Date:  2005-10       Impact factor: 2.673

4.  A randomised controlled trial of medroxyprogesterone acetate in mastalgia.

Authors:  P R Maddox; B J Harrison; J M Horobin; K Walker; R E Mansel; P E Preece; R I Nicholson
Journal:  Ann R Coll Surg Engl       Date:  1990-03       Impact factor: 1.891

5.  LHRH analogue for treatment of recurrent and refractory mastalgia.

Authors:  H Hamed; M Caleffi; M A Chaudary; I S Fentiman
Journal:  Ann R Coll Surg Engl       Date:  1990-07       Impact factor: 1.891

6.  Double-blind controlled trial of progesterone vaginal cream treatment for cyclical mastodynia in women with benign breast disease.

Authors:  C Nappi; P Affinito; C Di Carlo; G Esposito; U Montemagno
Journal:  J Endocrinol Invest       Date:  1992-12       Impact factor: 4.256

Review 7.  Drug therapy of mastalgia. What are the options?

Authors:  P A Holland; C A Gateley
Journal:  Drugs       Date:  1994-11       Impact factor: 9.546

8.  Role of centchroman in regression of mastalgia and fibroadenoma.

Authors:  Anita Dhar; Anurag Srivastava
Journal:  World J Surg       Date:  2007-06       Impact factor: 3.282

9.  Presence and possible significance of immunohistochemically demonstrable prolactin in breast apocrine metaplasia.

Authors:  S Kumar; R E Mansel; B Jasani
Journal:  Br J Cancer       Date:  1987-03       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.